NN111 - A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease

Project: Research project

Project Details

StatusActive
Effective start/end date9/15/218/31/27

Funding

  • Massachusetts General Hospital (U01 NS120901 AMD1 // U01 NS120901 AMD1)
  • National Institute of Neurological Disorders and Stroke (U01 NS120901 AMD1 // U01 NS120901 AMD1)